# SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Source: https://onco.cc/trials/nct06401005/  
OnCo record `nct06401005` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cadonilimab in triple-negative breast cancer, run by Hubei Cancer Hospital, now recruiting.

## Summary

SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) is a phase 2, interventional study registered as NCT06401005 by Hubei Cancer Hospital, with a registry enrolment figure of 51 participants, started 2024-11-28 and due to reach its primary completion in 2026-08-31. Interventions recorded: Cadonilimab (AK104). Conditions listed: Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06401005
- Phase: 2
- Setting: A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
- Sponsor: Hubei Cancer Hospital
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT06401005: https://clinicaltrials.gov/study/NCT06401005

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06401005.json